Amicus Therapeutics Statistics

Total Valuation

Amicus Therapeutics has a market cap or net worth of GBP 2.31 billion. The enterprise value is 2.47 billion.

Market Cap	2.31B
Enterprise Value	2.47B

Important Dates

The next estimated earnings date is Thursday, February 27, 2025.

Earnings Date	Feb 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+3.63%
Shares Change (QoQ)	+0.30%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	244.77M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 87.61, with an EV/FCF ratio of -105.17.

EV / Earnings	-31.66
EV / Sales	6.17
EV / EBITDA	87.61
EV / EBIT	211.48
EV / FCF	-105.17

Financial Position

The company has a current ratio of 3.15, with a Debt / Equity ratio of 2.49.

Current Ratio	3.15
Quick Ratio	2.20
Debt / Equity	2.49
Debt / EBITDA	12.79
Debt / FCF	-14.11
Interest Coverage	0.29

Financial Efficiency

Return on equity (ROE) is -67.09% and return on invested capital (ROIC) is 1.49%.

Return on Equity (ROE)	-67.09%
Return on Assets (ROA)	1.16%
Return on Capital (ROIC)	1.49%
Revenue Per Employee	712,433
Profits Per Employee	-151,079
Employee Count	517
Asset Turnover	0.64
Inventory Turnover	0.57

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.16% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-21.16%
50-Day Moving Average	9.76
200-Day Moving Average	10.47
Relative Strength Index (RSI)	50.14
Average Volume (20 Days)	890

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.94

Income Statement

In the last 12 months, Amicus Therapeutics had revenue of GBP 368.33 million and -78.11 million in losses. Loss per share was -0.26.

Revenue	368.33M
Gross Profit	331.45M
Operating Income	10.74M
Pretax Income	-51.00M
Net Income	-78.11M
EBITDA	17.23M
EBIT	10.74M
Loss Per Share	-0.26

Full Income Statement

Balance Sheet

The company has 186.34 million in cash and 331.76 million in debt, giving a net cash position of -145.42 million.

Cash & Cash Equivalents	186.34M
Total Debt	331.76M
Net Cash	-145.42M
Net Cash Per Share	n/a
Equity (Book Value)	133.42M
Book Value Per Share	0.45
Working Capital	253.92M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -19.78 million and capital expenditures -3.73 million, giving a free cash flow of -23.51 million.

Operating Cash Flow	-19.78M
Capital Expenditures	-3.73M
Free Cash Flow	-23.51M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 89.99%, with operating and profit margins of 2.92% and -21.21%.

Gross Margin	89.99%
Operating Margin	2.92%
Pretax Margin	-13.85%
Profit Margin	-21.21%
EBITDA Margin	4.68%
EBIT Margin	2.92%
FCF Margin	n/a

Dividends & Yields

Amicus Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.63%
Shareholder Yield	-3.63%
Earnings Yield	-3.37%
FCF Yield	-1.02%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Amicus Therapeutics has an Altman Z-Score of -0.41. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.41
Piotroski F-Score	n/a